HU169972B - - Google Patents

Info

Publication number
HU169972B
HU169972B HUBO1474A HUBO001474A HU169972B HU 169972 B HU169972 B HU 169972B HU BO1474 A HUBO1474 A HU BO1474A HU BO001474 A HUBO001474 A HU BO001474A HU 169972 B HU169972 B HU 169972B
Authority
HU
Hungary
Application number
HUBO1474A
Other languages
Hungarian (hu)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2260185A external-priority patent/DE2260185C3/de
Application filed filed Critical
Publication of HU169972B publication Critical patent/HU169972B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/18—Multi-enzyme systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F289/00—Macromolecular compounds obtained by polymerising monomers on to macromolecular compounds not provided for in groups C08F251/00 - C08F287/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C12N11/087—Acrylic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545—Synthetic resin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HUBO1474A 1972-12-08 1973-12-07 HU169972B (US06589383-20030708-C00041.png)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2260185A DE2260185C3 (de) 1971-06-09 1972-12-08 Trägergebundenes Protein und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
HU169972B true HU169972B (US06589383-20030708-C00041.png) 1977-03-28

Family

ID=5863935

Family Applications (1)

Application Number Title Priority Date Filing Date
HUBO1474A HU169972B (US06589383-20030708-C00041.png) 1972-12-08 1973-12-07

Country Status (12)

Country Link
US (1) US3969287A (US06589383-20030708-C00041.png)
JP (1) JPS5749197B2 (US06589383-20030708-C00041.png)
BE (1) BE808354A (US06589383-20030708-C00041.png)
CA (1) CA1023287A (US06589383-20030708-C00041.png)
CH (1) CH619003A5 (US06589383-20030708-C00041.png)
DK (1) DK141555C (US06589383-20030708-C00041.png)
HU (1) HU169972B (US06589383-20030708-C00041.png)
IL (1) IL43476A (US06589383-20030708-C00041.png)
IT (1) IT1045912B (US06589383-20030708-C00041.png)
SE (1) SE420498B (US06589383-20030708-C00041.png)
SU (1) SU524521A3 (US06589383-20030708-C00041.png)
ZA (1) ZA739318B (US06589383-20030708-C00041.png)

Families Citing this family (255)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593992A5 (US06589383-20030708-C00041.png) * 1972-12-23 1977-12-30 Roehm Gmbh
GB1550819A (en) * 1975-06-04 1979-08-22 Nat Res Dev Polymeric support for biogically active materials
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
US4108804A (en) * 1975-12-23 1978-08-22 Toru Seita Process for preparation of chromatography solid supports comprising a nucleic acid base-epoxy group containing porous gel
US4046723A (en) * 1976-04-22 1977-09-06 The Dow Chemical Company Azide bonding of a protein to a latex
US4179423A (en) * 1976-06-09 1979-12-18 Schenectady Chemicals, Inc. Water-soluble polyester imide resins
US4206261A (en) * 1976-06-09 1980-06-03 Schenectady Chemicals, Inc. Water-soluble polyester imide resin wire coating process
US4045384A (en) * 1976-07-23 1977-08-30 The Dow Chemical Company Method for forming an amide bond between a latex and protein
DE2708018A1 (de) * 1977-02-24 1978-09-07 Boehringer Mannheim Gmbh An polyamid fixiertes biologisch aktives protein und verfahren zu seiner herstellung
DE2862449D1 (en) * 1977-08-22 1984-11-22 Nat Res Dev Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
US4206286A (en) * 1977-11-14 1980-06-03 Technicon Instruments Corporation Immobilization of proteins on inorganic supports
US4338398A (en) * 1979-03-20 1982-07-06 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Immobilization of starch degrading enzymes
US4415665A (en) * 1980-12-12 1983-11-15 Pharmacia Fine Chemicals Ab Method of covalently binding biologically active organic substances to polymeric substances
DE3126551C2 (de) * 1981-07-04 1983-12-15 Rolf Dr. 8700 Würzburg Siegel Herstellungsverfahren für Materialien zur Immobilisierung von Proteinen und Kohlenhydratgruppen
US4506019A (en) * 1982-09-24 1985-03-19 Leeco Diagnostics, Inc. Activated polymer container means and assay method employing the same
US4596777A (en) * 1983-08-10 1986-06-24 E. R. Squibb & Sons, Inc. Process for preparing (3S)-3-[[[2-(protected or unprotected amino)-4-thiazolyl]acetyl]amino]-2-oxo-1-azetidinesulfonic acid and 4-substituted derivatives thereof
US4752638A (en) * 1983-11-10 1988-06-21 Genetic Systems Corporation Synthesis and use of polymers containing integral binding-pair members
US4609707A (en) * 1983-11-10 1986-09-02 Genetic Systems Corporation Synthesis of polymers containing integral antibodies
US4511478A (en) * 1983-11-10 1985-04-16 Genetic Systems Corporation Polymerizable compounds and methods for preparing synthetic polymers that integrally contain polypeptides
US4843010A (en) * 1983-11-10 1989-06-27 Genetic Systems Corporation Polymerization-induced separation immunoassays
US4711840A (en) * 1984-01-27 1987-12-08 Genetic Systems Corporation Polymerization-induced separation immunoassays
EP0142810B1 (en) * 1983-11-10 1994-02-16 Genetic Systems Corporation Polymerizable compounds integrally containing antibodies and their uses in polymerization induced separation immunoassays
JPH0820447B2 (ja) * 1984-01-27 1996-03-04 ジェネティック システムズ コーポレーション 液体混合物から物質を分離する方法及び免疫評価法
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4749647A (en) * 1984-06-22 1988-06-07 Genetic Systems Corporation Polymerization-induced separation assay using recognition pairs
DE3784592T2 (de) * 1986-08-07 1993-09-23 Minnesota Mining & Mfg Stabile, biologisch-aktive, fluorchemische emulsionen.
US4808530A (en) * 1986-09-05 1989-02-28 The Ohio State University Protein immobilization by adsorption of a hydrophobic amidine protein derivative to a hydrophobic surface
US4885250A (en) * 1987-03-02 1989-12-05 E. I. Du Pont De Nemours And Company Enzyme immobilization and bioaffinity separations with perfluorocarbon polymer-based supports
US5063109A (en) * 1988-10-11 1991-11-05 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DK0473961T3 (da) * 1990-08-15 1996-07-01 Abbott Lab Immunoassay-reagenser og fremgangsmåde til bestemmelse af cyklosporin
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5482996A (en) * 1993-12-08 1996-01-09 University Of Pittsburgh Protein-containing polymers and a method of synthesis of protein-containing polymers in organic solvents
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE275583T1 (de) * 1994-01-11 2004-09-15 Dyax Corp KALLIKREINHEMMENDE ßKUNITZ-DOMÄNEß-PROTEINE UND DERIVATEN DAVON
US6045797A (en) * 1994-03-14 2000-04-04 New York University Medical Center Treatment or diagnosis of diseases or conditions associated with a BLM domain
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5736624A (en) * 1994-12-02 1998-04-07 Abbott Laboratories Phosphatase activated crosslinking, conjugating and reducing agents; methods of using such agents; and reagents comprising phosphatase activated crosslinking and conjugating agents
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
US5837524A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polynucleotide products
US5807989A (en) * 1994-12-23 1998-09-15 New York University Methods for treatment or diagnosis of diseases or disorders associated with an APB domain
US6300482B1 (en) 1995-01-03 2001-10-09 Max-Flanck-Gesellschaft Zuer For{Overscore (D)}Erung Der MDKI, a novel receptor tyrosine kinase
US6565842B1 (en) * 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
JPH11511328A (ja) 1995-09-15 1999-10-05 ベイラー・カレッジ・オブ・メディスン ステロイドレセプター共活性化因子組成物および使用方法
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en) * 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
CA2277266A1 (en) 1997-01-31 1998-08-06 Genentech, Inc. O-fucosyltransferase
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
WO1998051793A1 (en) * 1997-05-15 1998-11-19 Genentech, Inc. Apo-2 RECEPTOR
JP2001523977A (ja) 1997-06-05 2001-11-27 ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ Ａｐａｆ−１、ｃｅｄ−４ヒト相同体、カスパーゼ−３の活性化因子
EP2083079A1 (en) 1997-06-18 2009-07-29 Genentech, Inc. Apo-2DcR
EP1007099A4 (en) * 1997-07-11 2004-11-24 Univ Brandeis METHOD FOR INDUCING APOPTOSE BY LOWERING THE THIAMINE MIRROR
US20030175856A1 (en) * 1997-08-26 2003-09-18 Genetech, Inc. Rtd receptor
JP2001513994A (ja) * 1997-08-26 2001-09-11 ジェネンテク・インコーポレイテッド Ｒｔｄレセプター
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
JP2002508962A (ja) 1998-01-15 2002-03-26 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド
ATE443723T1 (de) * 1998-06-12 2009-10-15 Genentech Inc Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
US6984719B1 (en) 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US6368793B1 (en) * 1998-10-14 2002-04-09 Microgenomics, Inc. Metabolic selection methods
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
HU228582B1 (en) 1998-10-23 2013-04-29 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US6982153B1 (en) 1998-12-03 2006-01-03 Targanta Therapeutics, Inc. DNA sequences from staphylococcus aureus bacteriophage 77 that encode anti-microbial polypeptides
US6861442B1 (en) 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
CN1370238A (zh) * 1999-06-16 2002-09-18 艾科斯有限公司 人聚(adp－核酸)聚合酶2的物质和方法
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
US20030138771A1 (en) * 1999-09-30 2003-07-24 Jerry Pelletier DNA sequences from S. pneumoniae bacteriophage DP1 that encode anti-microbal polypeptides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CN100399030C (zh) 1999-11-16 2008-07-02 杰南技术公司 用于vegf的elisa
US6743778B2 (en) 2000-04-21 2004-06-01 Amgen Inc. Apo-AI/AII peptide derivatives
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
US20030012782A1 (en) * 2000-08-11 2003-01-16 Gold Daniel P. Method and composition for altering a T cell mediated pathology
AU2002342669C1 (en) 2001-05-11 2010-10-07 Amgen, Inc. Peptides and related molecules that bind to TALL-1
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
EP2305312B1 (en) 2001-10-10 2015-03-04 ratiopharm GmbH Remodelling and glycoconjugation of follicle-stimulating hormone (FSH)
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20040054082A1 (en) * 2001-12-03 2004-03-18 Bank David H Toughened polymer blends with improved surface properties
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
TR201900937T4 (tr) 2002-08-28 2019-02-21 Dyax Corp Organların ve dokuların muhafaza edilmesine yönelik yöntem.
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
TW200526194A (en) * 2003-10-22 2005-08-16 Merz Pharma Gmbh & Co Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic Aβ peptides in amyloidopathies
DE602005027673D1 (de) 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
WO2005108989A2 (en) * 2004-04-16 2005-11-17 Genentech, Inc. Assay for antibodies
WO2005113554A2 (en) 2004-05-13 2005-12-01 Icos Corporation Method of preparing 3-phenyl-2-[9h-purin-6-ylamino)-methyl]-3h-quinazolin-4-one and substituted and related compounds
EP1769243A2 (en) * 2004-05-15 2007-04-04 Genentech, Inc. Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
CA2572765C (en) * 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
EA011879B1 (ru) 2004-09-24 2009-06-30 Эмджин Инк. МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
JP4652414B2 (ja) 2004-11-12 2011-03-16 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006069403A2 (en) 2004-12-22 2006-06-29 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
US20080287469A1 (en) * 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007056411A2 (en) * 2005-11-08 2007-05-18 Genentech, Inc. Method of producing pan-specific antibodies
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
CA2643693A1 (en) * 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
WO2008002591A2 (en) 2006-06-26 2008-01-03 Amgen Inc Methods for treating atherosclerosis
ATE531727T1 (de) 2006-09-18 2011-11-15 Compugen Ltd Bioaktive peptide und verfahren zu ihrer verwendung
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CN101523220B (zh) 2006-10-04 2016-09-21 健泰科生物技术公司 针对vegf的elisa
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US20080171344A1 (en) * 2006-12-22 2008-07-17 Kapsner Kenneth P Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
MX2009012609A (es) * 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
WO2009007848A2 (en) 2007-07-12 2009-01-15 Compugen Ltd. Bioactive peptides and method of using same
MY159075A (en) 2007-07-26 2016-12-15 Amgen Inc Modified lecithin-cholesterol acyltransferase enzymes
WO2009029716A1 (en) 2007-08-28 2009-03-05 Ramot At Tel Aviv University Peptides inducing a cd4i conformation in hiv gp120 while retaining vacant cd4 binding site
HUE044466T2 (hu) 2007-12-26 2019-10-28 Xencor Inc Megváltozott FcRn-kötõdési képességû Fc variánsok
WO2010027802A2 (en) 2008-08-25 2010-03-11 New York University Methods for treating diabetic wounds
US20100202963A1 (en) 2008-11-13 2010-08-12 Gallatin W Michael Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
WO2010080833A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
NZ595307A (en) 2009-03-24 2013-11-29 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
US8546409B2 (en) * 2009-04-20 2013-10-01 Gilead Calistoga Llc Methods of treatment for solid tumors
CN102647987A (zh) 2009-07-21 2012-08-22 吉里德卡利斯托加公司 使用pi3k抑制剂治疗肝脏障碍
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
EP2494356B1 (en) * 2009-10-26 2017-03-15 Genentech, Inc. Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
SG10201500895XA (en) 2009-11-05 2015-04-29 Rhizen Pharmaceuticals Sa Chromen-4-one Derivatives As Kinase Modulators
EP3459564B1 (en) 2010-01-06 2021-10-27 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
EP2547359B1 (en) 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Inhibitors of beta integrin-g protein alpha subunit binding interactions
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
EP4056193A1 (en) 2010-06-17 2022-09-14 New York University Therapeutic and cosmetic uses and applications of calreticulin
WO2012030738A2 (en) 2010-08-30 2012-03-08 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
KR102169651B1 (ko) 2011-01-06 2020-10-23 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
PE20140593A1 (es) 2011-03-16 2014-05-10 Amgen Inc Inhibidores potentes y selectivos de nav1.3 y nav1.7
JP2014516944A (ja) 2011-04-29 2014-07-17 ブリストル−マイヤーズ スクイブ カンパニー Ｉｐ１０抗体の用量漸増計画
MY168757A (en) 2011-05-04 2018-12-04 Rhizen Pharmaceuticals S A Novel compounds as modulators of protein kinases
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
BR112014006822B1 (pt) 2011-09-22 2021-05-18 Amgen Inc. Proteína de ligação ao antígeno cd27l, composição compreendendo uma proteína de ligação ao antígeno cd27l, ácido nucleico isolado, vetor de expressão, célula hospedeira recombinante procariótica, método de preparação de um conjugado de droga e anticorpo cd27l e uso de uma proteína de ligação ao antígeno cd27l
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP2834241B1 (en) 2012-03-05 2020-11-18 Gilead Calistoga LLC Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
US20150079100A1 (en) 2012-03-23 2015-03-19 Bristol-Myers Squibb Company Methods of treatments using ctla-4 antibodies
WO2013148373A1 (en) 2012-03-28 2013-10-03 Genentech, Inc. Anti-hcmv idiotypic antibodies and uses thereof
AP3908A (en) 2012-03-30 2016-11-24 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
JP6426107B2 (ja) 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド Ａｐｊ受容体アゴニストおよびその使用
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
ES2728936T3 (es) 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
WO2014122166A1 (en) 2013-02-06 2014-08-14 Pieris Ag Novel lipocalin-mutein assays for measuring hepcidin concentration
CA2901226C (en) 2013-02-18 2020-11-17 Vegenics Pty Limited Vascular endothelial growth factor binding proteins
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
AU2014233055B2 (en) 2013-03-15 2018-08-09 Board Of Regents, The University Of Texas System Inhibition of pulmonary fibrosis with nutlin-3a and peptides
KR102561553B1 (ko) 2013-03-15 2023-07-31 젠코어 인코포레이티드 이형이량체 단백질
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
PL2970449T3 (pl) 2013-03-15 2020-04-30 Amgen Research (Munich) Gmbh Jednołańcuchowe cząsteczki wiążące zawierające N-końcowy ABP
BR112015029643B1 (pt) 2013-05-30 2023-12-12 Kiniksa Phamaceuticals, Ltd Proteínas de ligação ao antígeno de receptor de oncostatina m, seu método de preparação e seu uso, composições farmacêuticas, ácido nucleico isolado, vetor de expressão e célula hospedeira procariótica recombinante
US20160216262A1 (en) 2013-09-12 2016-07-28 Institut National De La Sante Et De La Recherche Medicale Method for In Vitro Quantifying Allo-Antibodies, Auto-Antibodies and/or Therapeutic Antibodies
CA3184564A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2
MX2016002799A (es) 2013-09-13 2016-05-26 Genentech Inc Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
US10081682B2 (en) 2013-10-11 2018-09-25 Oxford Bio Therapeutics Ltd. Conjugated antibodies against LY75 for the treatment of cancer
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
ES2752552T3 (es) 2013-12-20 2020-04-06 Gilead Calistoga Llc Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
US10151754B2 (en) 2014-01-17 2018-12-11 Minomic International Ltd. Cell surface prostate cancer antigen for diagnosis
RU2693430C2 (ru) 2014-02-20 2019-07-02 Аллерган, Инк. Антитела к компоненту комплемента с5
CA2939586A1 (en) 2014-02-27 2015-09-03 Allergan, Inc. Complement factor bb antibodies
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
BR112016022385A2 (pt) 2014-03-28 2018-06-19 Xencor, Inc anticorpos específicos que se ligam a cd38 e cd3
ES2950789T3 (es) 2014-06-10 2023-10-13 Amgen Inc Polipéptidos de apelina
SG11201609877XA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
AR101400A1 (es) 2014-07-31 2016-12-14 Amgen Res (Munich) Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
US11661462B2 (en) 2014-07-31 2023-05-30 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody contructs
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh Constructos de anticuerpos para cdh19 y cd3
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
JP6865689B2 (ja) 2015-03-06 2021-04-28 ジェネンテック， インコーポレイテッド 超精製ＤｓｂＡ及びＤｓｂＣ、ならびにそれらの作製及び使用方法
WO2016149537A1 (en) 2015-03-17 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bank vole prion protein as a broad-spectrum substrate for rt-quic-based detection and discrimination of prion strains
UA126270C2 (uk) 2015-04-10 2022-09-14 Емджен Інк. Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин
WO2016164937A2 (en) 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
EA201792193A1 (ru) 2015-04-17 2018-05-31 Эмджен Рисерч (Мьюник) Гмбх Конструкции биспецифического антитела для cdh3 и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
WO2017040342A1 (en) 2015-08-28 2017-03-09 Genentech, Inc. Anti-hypusine antibodies and uses thereof
IL311156A (en) 2015-12-11 2024-04-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and their uses in the treatment of hereditary angioedema attack
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
LT3411404T (lt) 2016-02-03 2022-12-27 Amgen Research (Munich) Gmbh Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
SI3411402T1 (sl) 2016-02-03 2022-03-31 Amgen Research (Munich) Gmbh Konstrukti bispecifičnih protiteles BCMA in CD3, ki aktivirajo T celico
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
KR102625416B1 (ko) 2016-05-16 2024-01-15 다케다 파머수티컬 컴패니 리미티드 항-인자 ix 파두아 항체
EP3484923A1 (en) 2016-07-15 2019-05-22 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
KR20190104411A (ko) 2017-01-18 2019-09-09 제넨테크, 인크. 항-pd-l1 항체에 대한 이디오타입 항체 및 이의 용도
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
US11918650B2 (en) 2017-05-05 2024-03-05 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
CA3185107A1 (en) 2017-10-12 2019-04-18 Immunowake Inc. Vegfr-antibody light chain fusion protein
CA3082507A1 (en) 2017-12-11 2019-06-20 Amgen Inc. Continuous manufacturing process for bispecific antibody products
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
BR112020022122A2 (pt) 2018-04-30 2021-01-26 Medimmune Limited conjugados para alvejamento e eliminação de agregados
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
PE20211091A1 (es) 2018-07-02 2021-06-14 Amgen Inc Proteina de union al antigeno anti-steap1
MX2021001221A (es) 2018-07-30 2021-06-23 Amgen Res Munich Gmbh Administración prolongada de un constructo de anticuerpo biespecífico que se une a cd33 y cd3.
WO2020077212A1 (en) 2018-10-11 2020-04-16 Amgen Inc. Downstream processing of bispecific antibody constructs
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
WO2020252442A1 (en) 2019-06-13 2020-12-17 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
CA3150441A1 (en) 2019-08-13 2021-02-18 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
CA3152946A1 (en) 2019-09-10 2021-03-18 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
AU2020381536A1 (en) 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
JP2023507115A (ja) 2019-12-17 2023-02-21 アムジエン・インコーポレーテツド 治療における使用のためのデュアルインターロイキン－２／ｔｎｆ受容体アゴニスト
MX2022013310A (es) 2020-04-30 2022-11-14 Genentech Inc Anticuerpos especificos para kras y sus usos.
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
JP2023527972A (ja) 2020-05-29 2023-07-03 アムジエン・インコーポレーテツド Ｃｄ３３及びｃｄ３に結合する二重特異性コンストラクトの有害作用軽減投与
IL298599A (en) 2020-06-01 2023-01-01 Genentech Inc Methods for preparing extracellular vesicles and their uses
JP2023532266A (ja) 2020-06-23 2023-07-27 ジアンスー カニョン ファーマシューティカル カンパニー リミテッド 抗ｃｄ３８抗体及びその使用
EP4182688A1 (en) 2020-07-14 2023-05-24 F. Hoffmann-La Roche AG Assays for fixed dose combinations
EP4240768A2 (en) 2020-11-06 2023-09-13 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
JP2024513376A (ja) 2021-04-02 2024-03-25 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
CA3217180A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
CN113372514B (zh) * 2021-06-22 2022-06-14 安徽农业大学 一种刀豆蛋白聚合物水凝胶的制备方法、制得的水凝胶及其应用
TW202346368A (zh) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3574062A (en) * 1967-04-20 1971-04-06 Beckman Instruments Inc Method of immobilizing enzymes and product
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (US06589383-20030708-C00041.png) * 1967-12-20 1972-03-06 Pharmacia Ab
FR1603393A (US06589383-20030708-C00041.png) * 1967-12-27 1971-04-13
DE1908290C3 (de) * 1969-02-19 1982-04-08 Boehringer Mannheim Gmbh, 6800 Mannheim Acrylamid-mischpolymerisat
GB1316990A (en) * 1970-09-17 1973-05-16 Roche Products Ltd Imidazolyl derivatives
AT317424B (de) * 1971-06-09 1974-08-26 Boehringer Mannheim Gmbh Verfahren zur Herstellung von trägergebundenen Proteinen

Also Published As

Publication number Publication date
IL43476A (en) 1976-03-31
BE808354A (fr) 1974-06-07
JPS4986587A (US06589383-20030708-C00041.png) 1974-08-19
CH619003A5 (US06589383-20030708-C00041.png) 1980-08-29
JPS5749197B2 (US06589383-20030708-C00041.png) 1982-10-20
CA1023287A (en) 1977-12-27
SU524521A3 (ru) 1976-08-05
IT1045912B (it) 1980-06-10
DK141555C (da) 1980-09-22
SE420498B (sv) 1981-10-12
US3969287A (en) 1976-07-13
ZA739318B (en) 1974-11-27
DK141555B (da) 1980-04-21

Similar Documents

Publication Publication Date Title
JPS5749197B2 (US06589383-20030708-C00041.png)
FR2185498B3 (US06589383-20030708-C00041.png)
JPS5247858B2 (US06589383-20030708-C00041.png)
JPS4942755U (US06589383-20030708-C00041.png)
JPS5720532B2 (US06589383-20030708-C00041.png)
CS168032B2 (US06589383-20030708-C00041.png)
JPS5242583Y2 (US06589383-20030708-C00041.png)
JPS4988415U (US06589383-20030708-C00041.png)
JPS4933579U (US06589383-20030708-C00041.png)
JPS4947776U (US06589383-20030708-C00041.png)
AU448109B2 (US06589383-20030708-C00041.png)
JPS5229546Y2 (US06589383-20030708-C00041.png)
JPS4911299U (US06589383-20030708-C00041.png)
JPS4897699U (US06589383-20030708-C00041.png)
JPS493330U (US06589383-20030708-C00041.png)
JPS4992231U (US06589383-20030708-C00041.png)
JPS4956046U (US06589383-20030708-C00041.png)
NL7310462A (US06589383-20030708-C00041.png)
CH585165A5 (US06589383-20030708-C00041.png)
NL7303971A (US06589383-20030708-C00041.png)
BG18327A1 (US06589383-20030708-C00041.png)
CH577167A5 (US06589383-20030708-C00041.png)
BG18251A1 (US06589383-20030708-C00041.png)
BG18152A1 (US06589383-20030708-C00041.png)
BG18059A1 (US06589383-20030708-C00041.png)

Legal Events

Date Code Title Description
HU90 Patent valid on 900628